Orbis Medicines ApS

Based in Denmark, Orbis Medicines ApS specializes in developing innovative oral macrocycle drugs, leveraging its proprietary n Gen platform to provide alternatives to traditional injectable therapies. Founded in 2021, Orbis Medicines ApS is located in Frederiksberg, Denmark, focusing on drug development through its innovative platform. The company has raised EUR 90. 000 mn in its Series A funding round, led by New Enterprise Associates, with participation from Cormorant Asset Management, Forbion, Lilly Ventures, and Novo Holdings.

The total amount raised by the company is EUR 90. 000 mn, achieved through four funding deals, with the most recent funding round taking place on January 6, 2025. Sevan Habeshian is the founder, aiming to revolutionize oral medication delivery. Orbis Medicines specializes in the development of innovative oral macrocycle drugs, primarily through its proprietary platform known as n Gen.

The company's flagship product, the n Cycle, represents a new class of synthetic macrocycles optimized for oral bioavailability and membrane permeability. These compounds target various diseases typically requiring injectable biologic therapies, thereby providing effective alternatives for patients. The therapeutic applications for n Cycle encompass both intra- and extracellular targets, with initial focus areas aligned with diseases validated by existing blockbuster biologics. Orbis's products are marketed primarily in Europe and North America, catering to healthcare providers, pharmaceutical companies, and research institutions.

Orbis Medicines has successfully raised a total of EUR 116. 000 mn through strategic funding rounds, including a EUR 90. 000 mn Series A round. Revenue transactions are structured primarily through partnerships and collaborations with biotech firms seeking to leverage Orbis's advanced macrocycle capabilities.

The company engages in business-to-business transactions, working directly with pharmaceutical companies and research institutions to provide tailored drug development solutions. Specific pricing plans for products are structured around collaborative agreements that consider the complexity and customization of the compounds being developed. Flagship offerings such as the n Cycle are central to these partnerships, providing advancements in the landscape of oral biologics, appealing to clients looking to innovate in drug delivery systems. Orbis Medicines plans to utilize the EUR 90.

000 mn raised in the Series A funding round to further develop its oral macrocycle drugs. The company aims to launch new products designed to enhance therapeutic efficacy and broaden its product line. Additionally, it targets expansion into new markets across Europe and North America by the end of 2025, seeking to increase accessibility to its innovative treatment options. The recent funding will support these initiatives, allowing Orbis to advance its development efforts and establish new partnerships to bring its products to a wider audience.